Enriching CD3+ T Cells with Alerion™ Microbubble Cell Separation System
Updated on Oct 3, 2024 Share
A cell therapy company sought to improve its CD3+ T cell isolation process. To address the challenges it faces with its current method for recovery, purity, and processing time, it partnered with Akadeum Life Sciences to evaluate the Alerion™ Microbubble Cell Separation System in conjunction with the BioRise™ consumable and Human T Cell Leukopak Isolation Kit.
They chose to evaluate the Alerion™ Microbubble Cell Separation System due to:
- Better cell viability, health
- Fast, gentle workflow
- Superior purity and yield
Objective
The primary objective was to evaluate the effectiveness of the Alerion™ Microbubble Cell Separation System for enriching CD3+ T cells from apheresis samples. The focus was on achieving highly pure and viable CD3+ T cells post-isolation.
Kit Used
The Alerion™ Microbubble Cell Separation System and BioRise™ consumable were paired with Akadeum’s Human T Cell Leukopak Isolation Kit.
Experimental Overview
The study isolated T cells from washed apheresis material using the Alerion™ Microbubble Cell Separation System. Key performance metrics evaluated included the input and output percentages of CD3+ T cells and post-enrichment viability.
- Sample preparation: Apheresis samples were obtained and processed to remove red blood cells and platelets, resulting in washed apheresis material.
- Isolation and cell counting: A sample was taken and read on a NucleoCounter® NC-200™ cell counter to determine cell counts. The rest of the washed apheresis material was processed using the Alerion™ Microbubble Cell Separation System. T cells were enriched via the BioRise™ consumable paired with the Akadeum Human T Cell Leukopak Isolation Kit. The resulting enriched cells were then counted and assessed for viability.
Figure 1: Schematic of experimental design. Figure courtesy of the cell therapy company.
Key Findings
Enhanced Purity and Recovery for Better Cell Therapy Workflows
The Alerion™ Microbubble Cell Separation System, in combination with the Human T Cell Leukopak Isolation Kit and BioRise™ consumable, resulted in a 96.8% pure T cell population compared to the input material, which was at 34.6%.
This high output purity indicates that the Alerion™ Microbubble Cell Separation System effectively enriches CD3+ T cells for further therapeutic applications. Improved purity and recovery are critical for more efficient engineering of T cells, which in turn can enable better therapeutics.
High Viability, Better Cell Health
The viability of the CD3+ T cells post-enrichment was measured at 97.8%, demonstrating that the Alerion™ Microbubble Cell Separation System enriches the T cells without jeopardizing cell health. The efficiency and gentleness at which the Alerion™ system separates cells contribute to cell health. Healthier cells are better-engineered cells.
Figure 2: CD3+ T cell enrichment and viability. The concentration of CD3+ T cells increased from 34.6% to 96.8% using the Alerion™ Microbubble Cell Separation System, with post-enrichment viability of 97.8%. Figure courtesy of the cell therapy company.
Explore the Future of Cell Isolation With Akadeum
The Alerion™ Microbubble Cell Separation System, combined with the BioRise™ consumable and Human T Cell Leukopak Isolation Kit, effectively enriches CD3+ T cells with high purity and viability. This evaluation demonstrates the system’s efficiency in enhancing the cell isolation process, making it a valuable tool for improving the production of therapeutic T cells.
Akadeum Life Sciences is committed to advancing cell therapy through innovative solutions. Discover how the Alerion™ Microbubble Cell Separation System can enhance your cell isolation processes. For more information, contact our team for personalized assistance.
Interested in highly viable T Cells? Purchase one of our Cell Therapy Products.